Rain Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Highlights Recent Progress
March 03, 2022 16:05 ET
|
Rain Therapeutics Inc
– Quarter-end cash position of $140.2 million provides runway to complete all ongoing and planned clinical trials of milademetan, including an ample cash cushion for the Phase 3 MANTRA trial in...
Rain Therapeutics Doses First Patient in Phase 2 Basket Trial of Milademetan for MDM2-Amplified Advanced Solid Tumors (MANTRA-2)
November 19, 2021 08:00 ET
|
Rain Therapeutics Inc
NEWARK, Calif., Nov. 19, 2021 (GLOBE NEWSWIRE) -- Rain Therapeutics Inc. (NasdaqGS: RAIN), (“Rain”), a late-stage company developing precision oncology therapeutics, today announced that the first...
Rain Therapeutics Reports Third Quarter 2021 Financial Results and Highlights Recent Progress
November 10, 2021 08:00 ET
|
Rain Therapeutics Inc
New Phase 2 clinical trial planned for milademetan in Merkel cell carcinoma (MCC), the MANTRA-3 trial, to start in mid-2022 Quarter-end cash position of $150.1 million provides runway to advance...
Rain Therapeutics Plans Phase 2 Merkel Cell Carcinoma Clinical Trial (MANTRA-3) of Milademetan
November 09, 2021 08:00 ET
|
Rain Therapeutics Inc
The Merkel cell trial will be prioritized over the previously planned Phase 2 trial in patients with intimal sarcoma, and will evaluate milademetan in patients with IO-refractory disease Rain to host...
Rain Therapeutics to Report Third Quarter 2021 Financial Results and Highlights of Recent Progress on November 10, 2021
November 03, 2021 08:00 ET
|
Rain Therapeutics Inc
NEWARK, Calif., Nov. 03, 2021 (GLOBE NEWSWIRE) -- Rain Therapeutics Inc. (NasdaqGS: RAIN), (“Rain”), a late-stage company developing precision oncology therapeutics, today announced it will report...
Rain Therapeutics Hosting Research and Development (R&D) Day
October 25, 2021 08:00 ET
|
Rain Therapeutics Inc
NEWARK, Calif., Oct. 25, 2021 (GLOBE NEWSWIRE) -- Rain Therapeutics Inc., (NasdaqGS: RAIN), (“Rain”), a late-stage company developing precision oncology therapeutics, today announced that it will...
Rain Therapeutics Presents Data on Milademetan (RAIN-32) at the 2021 AACR-NCI-EORTC Virtual International Conference on Molecular Targets and Cancer Therapeutics
October 07, 2021 10:00 ET
|
Rain Therapeutics Inc
NEWARK, Calif., Oct. 07, 2021 (GLOBE NEWSWIRE) -- Rain Therapeutics Inc., (NasdaqGS: RAIN), (“Rain”), a late-stage company developing precision oncology therapeutics, today announced data on its...
Rain Therapeutics to Present on Milademetan at the 2021 AACR-NCI-EORTC Virtual International Conference on Molecular Targets and Cancer Therapeutics
October 04, 2021 08:00 ET
|
Rain Therapeutics Inc
NEWARK, Calif., Oct. 04, 2021 (GLOBE NEWSWIRE) -- NEWARK, Calif., October 1, 2021 (GLOBE NEWSWIRE) -- Rain Therapeutics Inc., (NasdaqGS: RAIN), (“Rain”), a late-stage company developing precision...
Rain Therapeutics to Present at the Cantor Fitzgerald Virtual Global Healthcare Conference
September 22, 2021 08:00 ET
|
Rain Therapeutics Inc
NEWARK, Calif., Sept. 22, 2021 (GLOBE NEWSWIRE) -- Rain Therapeutics Inc. (NasdaqGS: RAIN), (“Rain”), a late-stage company developing precision oncology therapeutics, today announced that Avanish...
Rain Therapeutics to Present at H.C. Wainwright 23rd Annual Global Investment Conference
September 09, 2021 08:00 ET
|
Rain Therapeutics Inc
NEWARK, Calif., Sept. 09, 2021 (GLOBE NEWSWIRE) -- Rain Therapeutics Inc. (NasdaqGS: RAIN) (“Rain”), a late-stage company developing precision oncology therapeutics, today announced that Avanish...